Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)
Eur J Cancer
.
2014 Mar;50(4):862-3.
doi: 10.1016/j.ejca.2013.12.001.
Epub 2014 Jan 10.
Authors
Antonio Gonzalez-Martin
1
,
Laurence Gladieff
2
,
Bengt Tholander
3
,
Daniel Stroyakovsky
4
,
Martin Gore
5
,
Giovanni Scambia
6
,
Ana Oaknin
7
,
Vesna Sneller
8
,
Ulrich Freudensprung
8
,
Sandro Pignata
9
;
OCTAVIA Investigators
Affiliations
1
GEICO and MD Anderson Cancer Center Spain, Madrid, Spain. Electronic address:
[email protected]
.
2
GINECO and Institut Claudius Regaud, Toulouse, France.
3
NSGO and Uppsala University Hospital, Uppsala, Sweden.
4
Moscow Oncology Hospital No. 62, Moscow, Russian Federation.
5
The Royal Marsden Hospital, London, UK.
6
Università Cattolica Roma, Rome, Italy.
7
Vall d'Hebron University Hospital, Barcelona, Spain.
8
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
9
MITO and Department of Urology and Gynecology, Istituto Nazionale Tumori Fondazione G. Pascale, IRCCS, Naples, Italy.
PMID:
24418723
DOI:
10.1016/j.ejca.2013.12.001
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Humans
Ovarian Neoplasms / drug therapy*